The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

By Kristensen L. E.   Christensen R.   Bliddal H.   Geborek P.   Danneskiold-Samsøe B.   Saxne T.  

Scandinavian Journal of Rheumatology, Vol. 36, Iss. 6, 2007-01 ,pp. : 411-417

Informa Healthcare

Access to resources Recommend Favorite

Infliximab in psoriatic arthritis

By Anandarajah Allen P   Ritchlin Christopher T  

Future Rheumatology, Vol. 2, Iss. 1, 2007-02 ,pp. : 13-22

Future Medicine

Access to resources Recommend Favorite

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

By Wick M. C.   Ernestam S.   Lindblad S.   Bratt J.   Klareskog L.   van Vollenhoven R. F.  

Scandinavian Journal of Rheumatology, Vol. 34, Iss. 5, 2005-10 ,pp. : 353-358

Informa Healthcare

Access to resources Recommend Favorite

Sustained response to etanercept after failing infliximab, in a patient with relapsing polychondritis with tracheomalacia

By Subrahmanyam P.   Balakrishnan C.   Dasgupta B.  

Scandinavian Journal of Rheumatology, Vol. 37, Iss. 3, 2008-01 ,pp. : 239-240

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of infliximab or adalimumab, versus abatacept, in patients with rheumatoid arthritis: ATTEST–AMPLE network randomized trial

By Christensen Robin   Tarp Simon   Furst Daniel E   Kristensen Lars E   Bliddal Henning  

International Journal of Clinical Rheumatology, Vol. 8, Iss. 6, 2013-12 ,pp. : 647-655

Future Medicine

Access to resources Recommend Favorite